<DOC>
	<DOCNO>NCT02756962</DOCNO>
	<brief_summary>The investigator prospectively determine whether relapse-free overall survival patient clear leukemia-associated mutation treat standard consolidation chemotherapy superior expect base historical control . The investigator also prospectively determine relapse-free overall survival patient clear mutation . Because relapse rate patient persistent mutation expect high , treatment either standard care consolidation therapy alone alloSCT permit , discretion treat physician .</brief_summary>
	<brief_title>Improving Risk Assessment AML With Precision Genomic Strategy Assess Mutation Clearance</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Age 1860 year . Considered suitable intensive ( cytotoxic ) induction candidate . Has previously untreated , de novo , nonM3 AML intermediaterisk disease ( IntermediateI IntermediateII ) define ELN criterion OR normal cytogenetics ( analysis 20 metaphase ) mutate NPM1 without FLT3ITD . Has undergone cytotoxic induction therapy In morphologic complete remission incomplete blood count recovery , morphologic complete remission postinduction 2 induction cycle define revise IWG criterion Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control , abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , must inform treat physician immediately . Able understand willing sign IRB approve write informed consent document . Willing comply treatment assignment : Intent proceed HiDAC consolidation LAM VAF &lt; 2.5 % Intent proceed either HiDAC consolidation allogeneic stem cell transplantation , discretion treat physician , LAM â‰¥2.5 % Diagnosis acute promyelocytic leukemia ( APL ) ( 15 ; 17 ) ( q22 ; q12 ) ; PMLRARA . Therapyrelated AML ( define occurrence AML due prior exposure chemotherapy radiation malignancy ) . Secondary AML ( define development AML patient antecedent hematological malignancy ) . Has medical psychosocial condition would prevent study compliance . Known seropositivity active viral infection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) . Patients seropositive hepatitis B vaccine eligible . History allergic reaction compound similar chemical biologic composition cytarabine . Pregnant and/or breastfeeding . Women childbearing potential must negative pregnancy test within 3 day sign consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>